Ariad workforce shrinks by 40%

Share this article:

Ariad Pharmaceuticals is firing 40% of its workforce. The company announced the cuts Friday, days after the company agreed to an FDA request that it halt all US marketing and distribution of its cancer drug, Iclusig. Concerns about blood clots prompted the FDA's request as well as forcing Ariad to idle a clinical trial earlier this month.

BioCentury reports that the EMA is reviewing the issue but has not advised doctors and patients to cease treatment.

Ariad CEO Harvey Berger said in a conference call last week that the clotting issue is not a new one, and that it appeared in the documents the FDA had access to when issuing its expedited 2012 approval.

The company told MM&M it will provide more information about the layoffs during this Tuesday's earnings call.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.